The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. It also explains how the Centers for Medicare & Medicaid Services will help ensure Medicare beneficiaries can access drugs at the negotiated prices from the first and second cycles when those prices become effective in 2026 and 2027, respectively. CMS in August announced lower prices for 10 drugs covered by Part D that were selected in the first round. AHA in July commented on the guidance for the program, expressing concern about CMS’ proposal to retrospectively effectuate access to the negotiated prices and its implications for the 340B program. AHA will share more information soon about specific implications of the final guidance for hospitals. 

Related News Articles

Headline
The Medicare Part A deductible for inpatient hospital services will increase by $44 in calendar year 2025 to $1,676, the Centers for Medicare & Medicaid…
Headline
The AHA Nov. 11 voiced strong support for the Centers for Medicare & Medicaid Services’ proposed plan for data collection and reporting requirements for…
Headline
In comments Nov. 12 to majority and minority leaders of the House and Senate, the AHA requested that Congress act on key priorities for hospitals and health…
Headline
Senators Bill Cassidy, R-La., and Maggie Hassan, D-N.H., Nov. 1 released a policy framework detailing a plan to impose site-neutral payments on hospitals. Site…
Headline
The Centers for Medicare & Medicaid Services Oct. 29 announced the Medicare Shared Savings Program yielded a program-record of more than $2.1 billion in…
Headline
A report released OCt. 23 by Kodiak Solutions found that Medicare Advantage plans classified three to four times as many hospital stays as observation visits…